Crossbow Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
At Crossbow Therapeutics, we develop immune cell engagers targeting pHLA complexes on cancer cells, expanding the reach of antibody therapeutics.
We have a top-tier, well-rounded top-tier team of experienced, talented and execution-drive individuals that span all aspects of drug discovery, drug development and company building, led by CEO Briggs Morrison.
The IND for our first program, CBX-250, a TCE for a tumor-specific target (CG) in various myeloid malignancies was accepted by the FDA in April '25, with our FPI projected this summer.
Our second program, now publicly disclosed as a T-cell engager targeting a pHLA from telomerase, a known oncogenic driver, relevant to most cancer types (with thus blockbuster potential), has progressed to IND-enabling studies, with CMC is ongoing.
Behind that, we have a rich pipeline that is progressing well.
We are open to partnering opportunities (both for assets as well as research/platform collaborations).
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}